Rollman E, Bråve A, Boberg A, Gudmundsdotter L, Engström G, Isaguliants M, Ljungberg K, Lundgren B, Blomberg P, Hinkula J, Hejdeman B, Sandström E, Liu M, Wahren B
Swedish Institute for Infectious Disease Control, Solna, Sweden.
Microbes Infect. 2005 Nov;7(14):1414-23. doi: 10.1016/j.micinf.2005.07.017. Epub 2005 Sep 29.
The viral diversity of HIV-1 is likely to require a vaccine strategy that induces broad cellular and humoral anti-HIV-1 immunity. Our strategy is based on multiple HIV-1 DNA immunogens together with adjuvant recombinant granulocyte-macrophage stimulating factor. This article describes pre-clinical and clinical work preceding the initiation of clinical HIV-1 phase I/II trials.
HIV-1的病毒多样性可能需要一种能诱导广泛的细胞和体液抗HIV-1免疫的疫苗策略。我们的策略基于多种HIV-1 DNA免疫原以及佐剂重组粒细胞-巨噬细胞刺激因子。本文描述了在启动HIV-1临床I/II期试验之前的临床前和临床工作。
Zotero 插件